See more : uniQure N.V. (0EE0.L) Income Statement Analysis – Financial Results
Complete financial analysis of Silverback Therapeutics, Inc. (SBTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silverback Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- coly Inc. (4175.T) Income Statement Analysis – Financial Results
- TVI Pacific Inc. (TVIPF) Income Statement Analysis – Financial Results
- Cape EMS Berhad (5311.KL) Income Statement Analysis – Financial Results
- Banco Bradesco S.A. (BBD) Income Statement Analysis – Financial Results
- Gossamer Bio, Inc. (GOSS) Income Statement Analysis – Financial Results
Silverback Therapeutics, Inc. (SBTX)
About Silverback Therapeutics, Inc.
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 18.38M | 61.50M | 24.58M | 21.51M | 14.80M |
| General & Administrative | 18.46M | 28.08M | 8.34M | 2.56M | 3.52M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.46M | 28.08M | 8.34M | 2.56M | 3.52M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 36.83M | 89.58M | 32.92M | 24.07M | 18.32M |
| Cost & Expenses | 36.83M | 89.58M | 32.92M | 24.07M | 18.32M |
| Interest Income | 0.00 | 0.00 | -29.00K | 100.00K | 43.00K |
| Interest Expense | -834.00K | 106.00K | -29.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 319.00K | 783.00K | 637.00K | 544.00K | 480.00K |
| EBITDA | -35.52M | -88.59M | -32.31M | -23.42M | -17.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -35.52M | -89.37M | -32.92M | -24.07M | -18.32M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 834.00K | 106.00K | -29.00K | 100.00K | 741.00K |
| Income Before Tax | -34.68M | -89.48M | -32.95M | -23.97M | -17.58M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -834.00K | 106.00K | -29.00K | 100.00K | 741.00K |
| Net Income | -33.85M | -89.58M | -32.95M | -23.97M | -17.58M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.85 | -30.81 | -11.33 | -4.90 | -3.59 |
| EPS Diluted | -0.85 | -30.81 | -11.33 | -4.90 | -3.59 |
| Weighted Avg Shares Out | 39.96M | 2.91M | 2.91M | 4.89M | 4.89M |
| Weighted Avg Shares Out (Dil) | 39.96M | 2.91M | 2.91M | 4.89M | 4.89M |
SVB Leerink Bullish On Silverback Therapeutics, Sees Diverse Pipeline
Notable Insider Buys Of the Past Week: Avis Budget, Biotech IPOs And More
Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
U.S. IPO Weekly Recap: The IPO Market Is Taught A Thing Or Two In An 8 IPO Week
Biotech IPOs Stay Hot With Seer, Silverback Set To Trade
Silverback Therapeutics prices IPO at $21/share, will raise $241M in 4th Wash. state IPO of 2020
Source: https://incomestatements.info
Category: Stock Reports